• contents
  • main menu
  • head menu
  • footer menu

KM Biologics

MENU
  • ABOUT USopen
    • ABOUT US
    • KM Biologics at a Glance
    • Our Business
    • Product History
    • President’s Message
    • Our Philosophy
    • Meiji Group Sustainability
    • Board of Directors
    • Locations
  • INNOVATIONSopen
    • INNOVATIONS
    • Our Scientists
  • PRODUCTSopen
    • PRODUCTS
    • Vaccines
    • Antitoxins and Antivenoms
    • Blood Plasma Products
    • Poultry
    • Swine
    • Bovine
    • Equine
    • Canine and Feline
  • NEWS
  • PARTNERSHIPS
  • CONTACT

HOME > NEWS

NEWS

  • 2021
  • 2018
Mar. 25, 2021
KM Biologics Announces Phase I Clinical Study Results of a Live Attenuated Tetravalent Dengue Vaccine (KD-382)Open new window
Dec. 21, 2018
Nature, November special issue — KM Biologics: Safeguarding public healthOpen new window
Oct. 31, 2018
KM Biologics launches new website

Page Top

  • JAPANESE
  • Terms and Conditions
  • Privacy Policy
  • © KM Biologics All Rights Reserved.
Meiji Holdings Co., Ltd.New window will be opened.